2 completed, 2 recruiting, 1 terminated. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Completed 1 |
| Phase 2 | 3 | Recruiting 2, Terminated 1 |
Follow Artios Pharma Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of ART0380 in Patients With Biologically Selected Solid Tumors ART0380 - Advanced Solid Tumor, Recurrent Endometrial Cancer | Phase 2 | Terminated | Artios Pharma Ltd | 36 | 2023-09-06 | 2025-11-06 |
| Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA) ART6043, Olaparib - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 / Phase 2 | Recruiting | Artios Pharma Ltd | 181 | 2023-06-30 | 2026-10-19 |
| A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors ART4215, Talazoparib, Niraparib - Advanced Cancer, Metastatic Cancer | Phase 1 | Completed | Artios Pharma Ltd | 93 | 2021-09-13 | 2026-01-27 |
| Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein Determination of ATM alteration status. - Solid Tumor, Unspecified, Adult | Completed | Artios Pharma Ltd | 229 | 2021-05-28 | 2022-08-01 | |
| A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors ART0380, Gemcitabine, Irinotecan - Advanced Cancer, Metastatic Cancer | Phase 1 / Phase 2 | Recruiting | Artios Pharma Ltd | 542 | 2021-01-27 | 2026-10-22 |
Neoplasm Metastasis (4) · Endometrial Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Acinar Cell (1) · Colorectal Neoplasms (1) · Fallopian Tube Neoplasms (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Ovarian Neoplasms (1)
Gemcitabine (1) · Irinotecan (1) · niraparib (1) · olaparib (1) · talazoparib (1)
United States (5) · United Kingdom (4) · Spain (3) · France (2)
Melissa Johnson, MD (2) · Antonio Gonzalez, MD, PHD (1) · Erika Hamilton, MD (1) · Kim Reiss Binder, MD (1) · Susanna Ulahannan, MD (1) · Timothy Yap, MBBS, PhD (1)
2023 (1)